Is a complete GSK research report available?

No complete published report is available for GSK plc (GSK) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

GSK Stock Analysis, Forecast & Valuation

Market cap	106.8B
Revenue (ttm)	44.1B
Net income (ttm)	6.4B
EPS (ttm)	$3.13
Shares out	4B
P/E (trailing)	16.7x
P/E (forward)	10.6x
Dividend	$1.77 (3.32%)
Volume	6,308,623

Beta	0.30

Price target	$58.1	+9.1%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All GSK indicators

Market & fundamental data

Available fields

283

Groups with data

Currency

GBP

Showing 283 of 283 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001131399
Company name	GSK plc
Country	United Kingdom
Country code	US
Cusip	37733W204
Employees	66,841
Employees Change	-1,788%
Employees Change Percent	-2.61
Enterprise value	$126.4B
Exchange	NYSE
Financial currency	GBP
First seen	2026-05-09
Industry	Drug Manufacturers - General
Industry PE	28.31
Industry PE Fwd	19.54
Isin	US37733W2044
Last refreshed	2026-07-30
Market cap	$106.8B
Market cap category	Large-Cap
Price	$53.22
Price currency	USD
Rev Per Employee	659,076.57x
Sector	Healthcare
Sector PE	45.63
Sector PE Fwd	24.38
Sic	2834
Symbol	GSK
Website	https://www.gsk.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.99%
EV Earnings	19.76x
EV Sales Forward	3.7x
EV/EBIT	14.64x
EV/EBITDA	14.64x
EV/FCF	13.73x
EV/Sales	2.87x
FCF yield	8.62%
Forward P/E	10.6x
P/B ratio	4.69x
P/E ratio	16.7x
P/S ratio	2.43x
PE Ratio10 Y	27.75x
PE Ratio3 Y	15.76x
PE Ratio5 Y	13.74x
PS Forward	3.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	19.48%
EBITDA Margin	19.48%
FCF margin	20.78%
Gross margin	73.49%
Gross Profit	$32.4B
Gross Profit Growth	7.62%
Gross Profit Growth Q	8.86%
Gross Profit Growth3 Y	5.21%
Gross Profit Growth5 Y	4.71%
Net Income	$6.4B
Net Income Growth	40.84%
Net Income Growth Q	-69.85%
Net Income Growth Quarters	6%
Net Income Growth Years	1%
Net Income Growth3 Y	-32.14%
Net Income Growth5 Y	1.9%
Pretax Margin	17.78%
Profit Margin	14.52%
Profit Per Employee	$95,696
Profitable Quarters	$6
Profitable Years	23
ROA	10.01
Roa5y	7.23
ROCE	16.18
ROE	33.38
Roe5y	32.1
ROIC	28.25
Roic5y	22.54

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.23%
Cagr15y	6.08%
Cagr1y	47.42%
Cagr20y	4.64%
Cagr3y	19.04%
Cagr5y	10.13%
Div CAGR10	-6.72%
Div CAGR3	8.44%
Div CAGR5	-7.99%
EPS Growth	42.63
EPS Growth Q	-69.52
EPS Growth Quarters	6
EPS Growth Years	1
EPS Growth3 Y	-32.1
EPS Growth5 Y	1.65
FCF Growth	7.6%
FCF Growth Q	28.37%
FCF Growth3 Y	27.3%
FCF Growth5 Y	5.89%
OCF Growth	7.86%
OCF Growth Q	28.34%
OCF Growth10 Y	8.39%
OCF Growth3 Y	22.02%
OCF Growth5 Y	5.62%
Revenue Growth	4.97x
Revenue Growth Q	5.3x
Revenue Growth Quarters	6x
Revenue Growth Years	5x
Revenue Growth3 Y	4.22x
Revenue Growth5 Y	3.19x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.55
Assets	$81.9B
Cash	$4.1B
Current Assets	$23.4B
Current Liabilities	$28.7B
Debt	$24.3B
Debt EBITDA	$2.81
Debt Equity	$1.06
Debt FCF	$2.64
Equity	$22.8B
Interest Coverage	9.84
Liabilities	$59.1B
Long Term Assets	$58.5B
Long Term Liabilities	$30.4B
Net Cash	$-20.1B
Net Cash By Market Cap	$-18.86
Net Debt EBITDA	$2.33
Net Debt Equity	$0.88
Net Debt FCF	$2.19
Tangible Book Value	$-8.7B
Tangible Book Value Per Share	$-2.16
WACC	5.4

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.82
Inventory Turnover	1.42
Net Working Capital	$-3.7B
Quick ratio	0.52
Working Capital	$-5.3B
Working Capital Turnover	$-13.19

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.36%
Dividend Growth	11.6%
Dividend Growth Years	2%
Dividend per share	$1.77
Dividend Years	54
Dividend Yield	3.32%
Ex Div Date	2026-05-15
Last Dividend	$0.45
Payout Frequency	Quarterly
Payout Ratio	56.46%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	82.9%
1Y total return	47.38%
200-day SMA	51.52
3Y total return	68.72%
50-day SMA	51.63
50-day SMA vs 200-day SMA	50over200
5Y total return	62.01%
All Time High	74.98
All Time High Change	-29.02%
All Time High Date	2007-04-20
All Time Low	28.47
All Time Low Change	86.97%
All Time Low Date	2022-09-26
ATR	1.35
Beta	0.3
Ch YTD	8.52
High	53.96
High52	61.7
High52 Date	2026-02-18
High52ch	-13.74%
Low	52.66
Low52	36.75
Low52 Date	2025-08-06
Low52ch	44.82%
Ma50ch	3.07%
Premarket Change Percent	0.57
Premarket Price	$54.02
Premarket Volume	122,027
Price vs 200-day SMA	3.3%
RSI	56.75
RSI Monthly	61.5
RSI Weekly	54.05
Sharpe ratio	1.43x
Sortino ratio	2.5
Total Return	4.68%
Tr YTD	10.35
Tr15y	142.38%
Tr1m	1.37%
Tr1w	4.85%
Tr3m	-1.42%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	2
Analyst Price Target Top	$70
Analyst Ratings	Hold
Analyst Ratings Top	Buy
Earnings EPS Estimate	$1.27
Earnings EPS Estimate Growth	2.42
Earnings Revenue Estimate	10,790,000,000x
Earnings Revenue Estimate Growth	1.22x
Operating Income	$12.9B
Operating Income Growth	57.16
Operating Income Growth Q	20.82
Operating Income Growth3 Y	9.77
Operating Income Growth5 Y	7.78
Operating margin	29.17
Price target	$58.08
Price Target Change	$9.13
Price Target Change Top	$31.53

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,856,024,329%
Float Percent	96.23%
Net Borrowing	1,034,302,819.8
Shares Insiders	0.06%
Shares Institutions	86.58%
Shares Out	4,007,000,000
Shares Qo Q	-0.29%
Shares Yo Y	-1.36%
Short Ratio	3.97
Short Shares	0.69

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$8.7B
Adjusted OCF	10,619,287,145.2
Average Volume	4,447,613.8x
Bv Per Share	5.84
CAPEX	$-1.9B
Ch10y	-5.76
Ch15y	-5.2
Ch1m	1.37
Ch1w	4.85
Ch1y	42.11
Ch20y	-23.45
Ch3m	-2.29
Ch3y	50.17
Ch5y	7.79
Ch6m	6.23
Change	-0.91%
Change From Open	-1.33
Close	53.71
Days Gap	0.43
Depreciation Amortization	1,510,749,409.1
Dollar Volume	335,744,916.1
Earnings Date	2026-07-28
Earnings Time	bmo
EBIT	$8.6B
EBITDA	$8.6B
EPS	$3.13
F Score	7
FCF	$9.2B
FCF EV Yield	7.28x
FCF Per Share	$2.3
Financing CF	-5,370,837,205
Fiscal Year End	December
Founded	1,715
Goodwill	9,850,566,597.8
Graham Number	28.52068
Graham Upside	-46.39
Income Tax	$850.5M
Investing CF	-6,261,111,850
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-07-28
Last Report Date	2026-06-30
Last Split Date	2022-07-19
Last Split Type	Reverse
Last10k Filing Date	2026-03-06
Lynch Fair Value	$15.93
Lynch Upside	-70.06
Ma150	53.13
Ma150ch	0.18%
Ma20	52.06
Ma20ch	2.22%
Net CF	-504,179,382
Next Earnings Date	2026-10-28
Open	53.94
Optionable	Yes
P FCF Ratio	11.61
P FCF Ratio SBC	12.27
P OCF Ratio	9.61
P OCF Ratio SBC	10.06
Payment Date	2026-07-09
Position In Range	43.08
Ppne	13,388,549,533.8
Pre Close	53.71
Price Date	2026-07-29
Price EBITDA	$12.38
Relative Volume	1.42x
Revenue	44,053,336,884x
SBC By Revenue	1.13x
Share Based Comp	496,218,655
Tax By Revenue	1.93x
Tax Rate	10.86%
Tr20y	147.86%
Tr6m	8.02%
Volume	6,308,623
Z Score	2.2

GSK plc (GSK)

Coverage state: Market snapshot only — no published research

Generate the first GSK analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · GSK

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GSK indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on GSK

Frequently asked questions